News & Views
Supply Agreement Opens Access to Oncology Medicines
Jan 10 2020
Following a recent agreement signing, global pharmaceutical company and service partner Inceptua Group now offer Bendalis GmbH’s range of generic oncology drugs and specialist therapeutic agents, enabling clinical trial sponsors quick access to Brexit-safe oncology standard of care medicines produced within the European Union.
“With this agreement Bendalis and Inceptua join forces to ensure optimal sourcing and supply of medicines for use in oncology clinical trials to our clients. Together, we share a mission to provide uninterrupted access for patients to high quality products through a secure and robust supply chain,” said Alan Raffensperger, CEO, Inceptua Group.
As a part of the agreement, Bendalis will maintain stock of specific products on a consignment basis, providing contingency against manufacturing issues, stock-out situations and mitigation of study delays which would impact both patients and sponsors.
“In the oncology space we experience a growing need and demand for products. We see Inceptua as the ideal partner to handle the distribution and help optimise the clinical trial supply for clients. A consistent and secure supply of products is a critical component in clinical trials and together we can offer a flexible yet reliable solution, helping clients minimise overage and reduce costs,” says Christian Parvany, CEO, Bendaliss.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China